• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

What Can Payers Do to Improve Biosimilar Uptake? Ryan Haumschild, PharmD, Weighs In

Video

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, explains how payers can play an essential role in improving biosimilar adoption.

Ryan Haumschild, PharmD, MS, MBA, director of pharmacy services at Emory Healthcare and Winship Cancer Institute, explains how payers can play an essential role in improving biosimilar adoption at the Academy of Managed Care Pharmacy's annual meeting in Chicago, Illinois.

Transcript:

What more should payers being doing to improve biosimilar uptake and adoption?

Haumschild: Our payer colleagues are so essential to what we do and I think they understand the value of biosimilars. And I think the more you can leverage biosimilars as a preferred agent by the plan, you can reduce total cost of care, you can create some flexibility to health care providers to choose the best biosimilar for them, as long as they know a biosimilar is going to be the preferred treatment, and then continue to leverage real world evidence of biosimilar use so we can continue to expand that rollout across many different practice settings.

Related Videos
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Dr Johnie Rose
Andrew Kuykendall, MD
Joseph Saseen, PharmD
Bridgette Picou, LVN, ACLPN, The Well Project
Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Carla Nester, MD, MSA, FASN
AJMC Q&A with Jason Bellet, Dr Geoffrey Rutledge, and Dan Nardi
Richard Nowak, MD, MS, Yale School of Medicine
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.